Board of the Pension Protection Fund Raises Stock Position in Zoetis Inc. (NYSE:ZTS)

Board of the Pension Protection Fund boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 214.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,400 shares of the company's stock after acquiring an additional 3,000 shares during the period. Board of the Pension Protection Fund's holdings in Zoetis were worth $724,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ZTS. Mission Wealth Management LP lifted its holdings in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. HUB Investment Partners LLC increased its position in Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC boosted its holdings in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after acquiring an additional 64 shares in the last quarter. Lindbrook Capital LLC grew its stake in shares of Zoetis by 1.8% during the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock worth $595,000 after acquiring an additional 65 shares during the last quarter. Finally, Ironwood Investment Management LLC increased its holdings in shares of Zoetis by 0.8% during the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock valued at $1,361,000 after acquiring an additional 68 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZTS has been the subject of a number of recent analyst reports. Piper Sandler lifted their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $212.13.

Insider Activity

In related news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president now owns 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.18% of the company's stock.

Zoetis Stock Performance

Zoetis stock traded up $0.38 during midday trading on Friday, hitting $156.17. 2,987,838 shares of the company were exchanged, compared to its average volume of 2,573,010. The business has a fifty day simple moving average of $160.25 and a two-hundred day simple moving average of $162.87. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The firm has a market capitalization of $69.53 billion, a PE ratio of 28.04, a price-to-earnings-growth ratio of 2.61 and a beta of 0.94. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.